Explore 3 Stock Ideas & Industry Insights Download Free Report

Greenwich Lifesciences Inc

Company price
18.0 USD 4.24 ( 30.81%)
Last update at 2026-11-17T17:54:00Z
VOLUME
873634
Market Cap
236.17M

Momentum Score

…

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
15.73
Low
19.28
High
52 Week Price Range
7.78
Low
34.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Greenwich Lifesciences, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ developing therapeutic candidates. Long-term growth drivers include advancement of research and development programs, successful commercialization of any approved products, and strategic partnerships that could expand the pipeline. Investors may find exposure to potential upside from program progress and partnership outcomes attractive while accepting typical early-stage biotech volatility.

The most important investment risks are clinical and regulatory setbacks, the need for additional financing and resulting dilution, a limited operating history and challenges in achieving commercial execution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
13.76
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-986.32%
Net Debt
-6.18M
ROCE
-5480.55%
Diluted EPS TTM
-1.59

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.36M -15.79M -8.89M -7.83M -4.57M
Net income -19.36M -15.79M -8.89M -7.61M -4.54M
Selling general administrative 2.23M 3.06M 1.63M 1.56M 1.04M
Selling and marketing expenses - - 0.00M - -
Gross profit -0.00M -0.00M -0.00M - -
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit -19.36M -15.79M -9.33M -8.04M -4.60M
Ebitda -19.36M -15.79M -9.32M -8.04M -4.59M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M 0.00M
Non operating income net other - - - - 0.03M
Operating income -19.45M -16.01M -9.33M -8.04M -4.60M
Other operating expenses 19.45M 16.01M 9.33M 8.04M 4.60M
Interest expense - - - 0.22M 0.03M
Interest income 0.09M 0.22M 0.45M 0.22M 0.03M
Net interest income 0.09M 0.22M 0.45M 0.22M 0.03M
Income tax expense - - -0.00M -0.22M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 19.45M 16.01M 9.33M 8.04M 4.60M
Cost of revenue 0.00M 0.00M 0.00M - -
Total other income expense net 0.09M 0.22M 0.44M 0.22M 0.03M
Net income from continuing ops -19.36M -15.79M -8.94M -7.83M -4.57M
Net income applicable to common shares - - - - -4.57M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.18M 4.09M 6.99M 13.48M 27.22M
Intangible assets - 0.00M 0.01M 0.01M 0.01M
Total liab 5.82M 1.56M 0.29M 0.26M 0.39M
Total stockholder equity 0.35M 2.53M 6.70M 13.21M 26.83M
Other current liab 0.95M 0.38M 0.26M 0.26M 0.16M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -87.14M -66.15M -50.36M -41.47M -33.65M
Other assets - 0.00M 0.00M -0.01M -0.01M
Cash 6.18M 4.09M 6.99M 13.47M 27.20M
Total current liabilities 5.82M 1.56M 0.29M 0.26M 0.39M
Net debt -6.18M -4.09M -6.99M -13.47M -27.20M
Other stockholder equity 87.48M 68.67M 57.05M 54.67M 60.47M
Total current assets 6.18M 4.09M 6.99M 13.47M 27.20M
Net tangible assets - - - - 26.82M
Accounts payable 4.87M 1.18M 0.04M 0.00M 0.22M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - - 0.01M
Retained earnings total equity - - - - -33.65M
Non currrent assets other - - 0.00M - -
Non current assets total 0.00M 0.00M 0.01M 0.01M 0.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - - -0.39M
Net borrowings - - - - -0.28M
Total cash from financing activities 12.00M 4.37M 0.00M -7.54M 2.84M
Change to operating activities - - - - 0.14M
Net income -19.36M -15.79M -8.89M -7.83M -4.57M
Change in cash 2.09M -2.90M -6.48M -13.74M -1.46M
Begin period cash flow 4.09M 6.99M 13.47M 27.20M 28.66M
End period cash flow 6.18M 4.09M 6.99M 13.47M 27.20M
Total cash from operating activities -9.91M -7.27M -6.48M -6.20M -4.29M
Issuance of capital stock 11.85M 4.37M 0.00M - 3.11M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Sale purchase of stock - - 0.00M -7.54M 3.11M
Other cashflows from financing activities 12.00M 4.37M - - -0.28M
Change to netincome - - - - 0.66M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash and cash equivalents changes - - - - -1.46M
Change in working capital 2.64M 1.27M 0.03M -0.12M -0.39M
Stock based compensation 6.80M 7.25M 2.38M 1.74M 0.66M
Other non cash items 2.64M 1.27M 0.04M - -0.38M
Free cash flow -9.91M -7.27M -6.48M -6.20M -4.29M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
GLSI
Greenwich Lifesciences Inc
4.24
30.81%
18.00 - - - 75.58 -21.23
NVO
Novo Nordisk A/S
-0.80
1.91%
40.80 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-2.08
0.39%
535.71 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
9.09
0.95%
961.49 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Greenwich Lifesciences Inc

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Building 14, Stafford, TX, United States, 77477

832-819-3232

4

Name Title Year Born
Mr. Snehal S. Patel CEO, CFO & Director 1963
Mr. Eric Rothe Founder & Independent Director 1975
Dr. Frank Joseph Daugherty M.D. Chief Medical Officer & Director 1950
Dr. Jaye L. Thompson Ph.D. VP of Clinical & Regulatory Affairs 1966
Dr. Christine T. Fischette Ph.D. VP of Bus. Devel. 1951
Dr. Jaye L. Thompson Ph.D. Vice President Clinical & Regulatory Affairs 1966
Dr. Christine T. Fischette Ph.D. VP of Business Development 1951
Mr. Snehal S. Patel CEO, CFO & Director 1964
Dr. Frank Joseph Daugherty M.D. Chief Medical Officer & Director 1951

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…